Compare · ALBO vs NVO
ALBO vs NVO
Side-by-side comparison of Albireo Pharma Inc. (ALBO) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ALBO and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.15B, about 348.0x ALBO ($526.3M).
- NVO has hit the wire 8 times in the past 4 weeks while ALBO has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 6 for ALBO).
- Company
- Albireo Pharma Inc.
- Novo Nordisk A/S
- Price
- $44.29-0.02%
- $41.01-4.51%
- Market cap
- $526.3M
- $183.15B
- 1M return
- -
- -10.44%
- 1Y return
- -
- -45.66%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2007
- News (4w)
- 0
- 8
- Recent ratings
- 6
- 25
Albireo Pharma Inc.
Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. Its lead product candidate is odevixibat, an ileal bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating patients with progressive familial intrahepatic cholestasis, as well as for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases. The company is also developing Elobixibat for the treatment of chronic constipation and other functional diseases, and nonalcoholic steatohepatitis. It has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat. The company is headquartered in Boston, Massachusetts.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest ALBO
- SEC Form SC 13G/A filed by Albireo Pharma Inc. (Amendment)
- SEC Form SC 13G/A filed by Albireo Pharma Inc. (Amendment)
- SEC Form 15-12G filed by Albireo Pharma Inc.
- SEC Form EFFECT filed by Albireo Pharma Inc.
- SEC Form EFFECT filed by Albireo Pharma Inc.
- SEC Form EFFECT filed by Albireo Pharma Inc.
- SEC Form EFFECT filed by Albireo Pharma Inc.
- SEC Form EFFECT filed by Albireo Pharma Inc.
- SEC Form 4: Chiswell David closing all direct ownership in the company
- SEC Form 4 filed by Alesina Susan
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care